Skip to main content
. 2017 Dec 4;8(68):112917–112927. doi: 10.18632/oncotarget.22872

Figure 1. WM cell lines are not responsive to lenalidomide and pomalidomide treatments.

Figure 1

(A) Viability (MTS) of the MM or WM cell lines treated with lenalidomide (left) or pomalidomide (right) for 48 hours. Dots represent the mean of three different experiments +/- SD. (B) Quantity relative of annexin V positive and PI negative cells after 48 hours treatment of lenalidomide (left) or pomalidomide (right) at the indicated concentrations. Histograms represent the mean of six different experiments +/- SEM. *: p<0.05. (C) Viability (MTS) of CD19 positive PBMCs isolated from three different WM patients treated with lenalidomide (1μM, left) or pomalidomide (0.1μM, right) for 48 hours. Error bars show standard deviation of triplicates.